1
|
Fedyanin M, Elsnukaeva H, Demidova I, Stroyakovskiy D, Shelygin Y, Tsukanov A, Panina M, Moiseenko F, Karpenko E, Bolotina L, Kudryavtseva A, Filipenko M, Oskorbin I, Vladimirova L, Timoshkina N, Kit O, Stroganova A, Dranko S, Tryakin A, Tjulandin S. 448P Efficacy of combinations of BRAF inhibitors and anti-EGFR antibodies in metastatic colorectal carcinoma (mCRC) patients with mBRAF in the real clinical practice. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
2
|
Gogas H, Dréno B, Larkin J, Demidov L, Stroyakovskiy D, Eroglu Z, Francesco Ferrucci P, Pigozzo J, Rutkowski P, Mackiewicz J, Rooney I, Voulgari A, Troutman S, Pitcher B, Guo Y, Yan Y, Castro M, Mulla S, Flaherty K, Arance A. Cobimetinib plus atezolizumab in BRAF V600 wild-type melanoma: primary results from the randomized phase III IMspire170 study. Ann Oncol 2020; 32:384-394. [PMID: 33309774 DOI: 10.1016/j.annonc.2020.12.004] [Citation(s) in RCA: 67] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2020] [Revised: 12/01/2020] [Accepted: 12/02/2020] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND Emerging data suggest that the combination of MEK inhibitors and immunotherapeutic agents may result in improved efficacy in melanoma. We evaluated whether combining MEK inhibition and immune checkpoint inhibition was more efficacious than immune checkpoint inhibition alone in patients with previously untreated BRAFV600 wild-type advanced melanoma. PATIENTS AND METHODS IMspire170 was an international, randomized, open-label, phase III study. Patients were randomized 1 : 1 to receive cobimetinib (60 mg, days 1-21) plus anti-programmed death-ligand 1 atezolizumab (840 mg every 2 weeks) in 28-day cycles or anti-programmed death-1 pembrolizumab (200 mg every 3 weeks) alone until loss of clinical benefit, unacceptable toxicity, or consent withdrawal. The primary outcome was progression-free survival (PFS), assessed by an independent review committee in the intention-to-treat population. RESULTS Between 11 December 2017, and 29 January 2019, 446 patients were randomized to receive cobimetinib plus atezolizumab (n = 222) or pembrolizumab (n = 224). Median follow-up was 7.1 months [interquartile range (IQR) 4.8-9.9] for cobimetinib plus atezolizumab and 7.2 months (IQR 4.9-10.1) for pembrolizumab. Median PFS was 5.5 months [95% confidence interval (CI) 3.8-7.2] with cobimetinib plus atezolizumab versus 5.7 months (95% CI 3.7-9.6) with pembrolizumab [stratified hazard ratio 1.15 (95% CI 0.88-1.50); P = 0.30]. Hazard ratios for PFS were consistent across prespecified subgroups. In exploratory biomarker analyses, higher tumor mutational burden was associated with improved clinical outcomes in both treatment arms. The most common grade 3-5 adverse events (AEs) were increased blood creatine phosphokinase (10.0% with cobimetinib plus atezolizumab versus 0.9% with pembrolizumab), diarrhea (7.7% versus 1.9%), rash (6.8% versus 0.9%), hypertension (6.4% versus 3.7%), and dermatitis acneiform (5.0% versus 0). Serious AEs occurred in 44.1% of patients with cobimetinib plus atezolizumab and 20.8% with pembrolizumab. CONCLUSION Cobimetinib plus atezolizumab did not improve PFS compared with pembrolizumab monotherapy in patients with BRAFV600 wild-type advanced melanoma.
Collapse
Affiliation(s)
- H Gogas
- First Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
| | - B Dréno
- Dermatology Department, CHU Nantes, CIC 1413, CRCINA, University Nantes, Nantes, France
| | - J Larkin
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - L Demidov
- N.N. Blokhin Russian Cancer Research Center, Ministry of Health, Moscow, Russia
| | - D Stroyakovskiy
- Moscow City Oncology Hospital #62 of Moscow Healthcare Department, Moscow Oblast, Russia
| | - Z Eroglu
- Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
| | | | - J Pigozzo
- Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - P Rutkowski
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | - J Mackiewicz
- Department of Medical and Experimental Oncology, Poznan University of Medical Sciences, and Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Center, Poznan, Poland
| | - I Rooney
- Genentech, Inc., South San Francisco, USA
| | - A Voulgari
- Roche Products Ltd, Welwyn Garden City, UK
| | - S Troutman
- Genentech, Inc., South San Francisco, USA
| | - B Pitcher
- Hoffmann-La Roche Ltd., Mississauga, Canada
| | - Y Guo
- Genentech, Inc., South San Francisco, USA
| | - Y Yan
- Genentech, Inc., South San Francisco, USA
| | - M Castro
- Genentech, Inc., South San Francisco, USA
| | - S Mulla
- Hoffmann-La Roche Ltd., Mississauga, Canada
| | - K Flaherty
- Massachusetts General Hospital Cancer Center, Boston, USA
| | - A Arance
- Department of Medical Oncology and IDIBAPS, Hospital Clínic Barcelona, Barcelona, Spain
| |
Collapse
|
3
|
Reck M, Mok T, Socinski M, Jotte R, Lim DT, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodriguez-Abreu D, Moro-Sibilot D, Thomas C, Barlesi F, Finley G, Shankar G, Yu W, Merritt D, Nishio M. 1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1607] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
4
|
Ascierto P, Robert C, Lewis K, Gutzmer R, Stroyakovskiy D, Gogas H, Protsenko S, Pereira R, Eigentler T, Rutkowski P, Demidov L, Manikhas GM, McNally V, Forbes H, Shah K, Yan Y, McArthur G. 1102P Clinical benefit in BRAFV600 mutation-positive melanoma defined by programmed death ligand 1 (PD-L1) and/or lactate dehydrogenase (LDH) status: Exploratory analyses from the IMspire150 study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1225] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
5
|
Van Cutsem E, Danielewicz I, Saunders MP, Pfeiffer P, Argilés G, Borg C, Glynne-Jones R, Punt CJA, Van de Wouw AJ, Fedyanin M, Stroyakovskiy D, Kroening H, Garcia-Alfonso P, Wasan H, Falcone A, Kanehisa A, Egorov A, Aubel P, Amellal N, Moiseenko V. Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study. Ann Oncol 2020; 31:1160-1168. [PMID: 32497736 DOI: 10.1016/j.annonc.2020.05.024] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Revised: 05/20/2020] [Accepted: 05/22/2020] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND We designed an open-label, noncomparative phase II study to assess the safety and efficacy of first-line treatment with trifluridine/tipiracil plus bevacizumab (TT-B) and capecitabine plus bevacizumab (C-B) in untreated patients with unresectable metastatic colorectal cancer (mCRC) who were not candidates for combination with cytotoxic chemotherapies. PATIENTS AND METHODS From 29 April 2016 to 29 March 2017, 153 patients were randomly assigned (1:1) to either TT-B (N = 77) or C-B (N = 76). The primary end point was progression-free survival (PFS). The primary PFS analysis was performed after 100 events (radiological progression or death) were observed. Secondary end points included overall survival (OS), quality of life (QoL; QLQ-C30 and QLQ-CR29 questionnaires), and safety. RESULTS Median (range) duration of treatment was 7.8 (6.0-9.7) months and 6.2 (4.1-9.1) months in the TT-B and C-B groups, respectively. Median (range) PFS was 9.2 (7.6-11.6) and 7.8 (5.5-10.1) months, respectively. Median (range) OS was 18 (15.2 to NA) and 16.2 (12.5 to NA) months, respectively. QoL questionnaires showed no relevant changes over time for either treatment. Therapies were well tolerated. Patients receiving TT-B had more grade ≥3 neutropenia (47% versus 5% with C-B). Patients receiving C-B had more grade ≥3 hand-foot syndrome (12% versus 0% with TT-B) and grade ≥3 diarrhea (8% versus 1% with TT-B), consistent with the known safety profiles of these agents. CONCLUSION TT-B treatment showed promising clinical activity in untreated patients with unresectable mCRC ineligible for intensive therapy, with an acceptable safety profile and no clinically relevant changes in QoL. CLINICAL TRIAL INFORMATION NCT02743221 (ClinicalTrials.gov).
Collapse
Affiliation(s)
- E Van Cutsem
- University Hospitals Leuven and KU Leuven, Leuven, Belgium.
| | - I Danielewicz
- Szpitale Wojewodzkie w Gdyni/Gdansk Medical University, Gdynia, Poland
| | - M P Saunders
- Christie Hospital NHS Foundation Trust, Manchester, UK
| | - P Pfeiffer
- Odense University Hospital, Odense, Denmark
| | - G Argilés
- Vall d'Hebrón Institute of Oncology and Vall d'Hebrón University Hospital, Barcelona, Spain
| | - C Borg
- University Hospital Besançon, Besançon, France
| | | | - C J A Punt
- Amsterdam University Medical Centers, Amsterdam
| | - A J Van de Wouw
- VieCuri Medisch Centrum Noord-Limburg, Venlo, The Netherlands
| | - M Fedyanin
- NN Blokhin National Medical Research Center of Oncology, Moscow, Russia
| | | | - H Kroening
- Schwerpunktpraxis für Haematologie und Onkologie Hasselbachplatz, Magdeburg, Germany
| | | | - H Wasan
- Hammersmith Hospital, Imperial College London, London, UK
| | - A Falcone
- University Hospital of Pisa, Department of Oncology, Pisa, Italy
| | - A Kanehisa
- Institut de Recherches Internationales Servier, Suresnes, France
| | - A Egorov
- Institut de Recherches Internationales Servier, Suresnes, France
| | - P Aubel
- Institut de Recherches Internationales Servier, Suresnes, France
| | - N Amellal
- Institut de Recherches Internationales Servier, Suresnes, France
| | - V Moiseenko
- Saint-Petersburg Scientific Practical Center for Specialized Medical Care, St Petersburg, Russia
| |
Collapse
|
6
|
Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalá M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 2019; 30:1848. [PMID: 31406976 PMCID: PMC6927319 DOI: 10.1093/annonc/mdz221] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
|
7
|
Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Abreu DR, Hussein M, Soo R, Conter H, Kozuki T, Huang K, Graupner V, Sun S, Hoang T, Jessop H, Mccleland M, Ballinger M, Sandler A, Socinski M. OA14.02 IMpower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.484] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
8
|
Stebbing J, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskiy D, Pikiel J, Eniu A, Komov D, Lee S, Kim M, Kim S, Park S, Bae J, Esteva F. 3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz240.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Esteva FJ, Baranau YV, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskiy D, Pikiel J, Eniu AE, Li RK, Rusyn AV, Tiangco B, Lee SJ, Lee SY, Yu SY, Stebbing J. Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial. Cancer Chemother Pharmacol 2019; 84:839-847. [PMID: 31428820 PMCID: PMC6768896 DOI: 10.1007/s00280-019-03920-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Accepted: 07/30/2019] [Indexed: 12/12/2022]
Abstract
PURPOSE Neoadjuvant CT-P6, a trastuzumab biosimilar, demonstrated equivalent efficacy to reference trastuzumab in a phase 3 trial of HER2-positive early-stage breast cancer (EBC) (NCT02162667). We report post hoc analyses evaluating pathological complete response (pCR) and breast pCR alongside additional efficacy and safety measures. METHODS Following neoadjuvant treatment and surgery, patients received adjuvant CT-P6 or trastuzumab (6 mg/kg) every 3 weeks for ≤ 1 year. RESULTS In total, 271 and 278 patients received CT-P6 and trastuzumab, respectively. pCR and breast pCR rates were comparable between treatment groups regardless of age, region, or clinical stage. Overall, 47.6% (CT-P6) and 52.2% (trastuzumab) of patients experienced study drug-related treatment-emergent adverse events (TEAEs), including 17 patients reporting heart failure (CT-P6: 10; trastuzumab: 7). Two CT-P6 and three trastuzumab patients discontinued adjuvant treatment due to TEAEs. CONCLUSION Adjuvant CT-P6 demonstrated comparable efficacy and safety to trastuzumab at 1 year in patients with HER2-positive EBC, supporting CT-P6 and trastuzumab comparability.
Collapse
Affiliation(s)
- F J Esteva
- Perlmutter Cancer Center, NYU Langone Health, 160 E 34th Street, New York, 10016, USA.,New York University Langone Medical Center, 550 1st Avenue, New York, 10016, USA
| | - Y V Baranau
- Department of Oncology, Belarusian State Medical University, 220013, Minsk, Belarus
| | - V Baryash
- Department of Oncology, Belarusian State Medical University, 220013, Minsk, Belarus
| | - A Manikhas
- City Clinical Oncology Dispensary, Saint Petersburg, 198255, Russian Federation
| | - V Moiseyenko
- GBUZ Saint Petersburg Clinical Research Center of Specialised Types of Care (Oncology), Saint Petersburg, 197758, Russian Federation
| | - G Dzagnidze
- S. Khechinashvili University Clinic, Ltd, 0177, Tbilisi, Georgia
| | - E Zhavrid
- N.N. Alexandrov National Cancer Centre of Belarus, 223040, Minsk Region, Belarus
| | - D Boliukh
- Vinnytsya Regional Clinical Oncology Dispensary, Vinnytsia, 21029, Ukraine
| | - D Stroyakovskiy
- Moscow City Oncology Hospital, Moscow, 143423, Russian Federation
| | - J Pikiel
- Wojewodzkie Centrum Onkologii, 80-219, Gdańsk, Poland
| | - A E Eniu
- Cancer Institute "Ion Chiricuta", 400015, Cluj-Napoca, Romania
| | - R K Li
- St. Luke's Medical Center, 1102, Quezon City, Philippines
| | - A V Rusyn
- Transcarpathian Regional Clinical Oncology Dispensary, Transcarpathian, 88000, Ukraine
| | - B Tiangco
- The Medical City, Ortigas Avenue, Pasig City, Philippines
| | - S J Lee
- CELLTRION, Inc., Incheon, 22014, Republic of Korea
| | - S Young Lee
- CELLTRION, Inc., Incheon, 22014, Republic of Korea
| | - S Y Yu
- CELLTRION, Inc., Incheon, 22014, Republic of Korea
| | - J Stebbing
- Division of Cancer, Imperial Centre for Translational and Experimental Medicine, Du Cane Road, London, W12 0HS, UK. .,Imperial College Healthcare NHS Trust, Charing Cross Hospital, Fulham Palace Road, London, W6 8RF, UK.
| |
Collapse
|
10
|
Titova T, Besova N, Artamonova E, Stroyakovskiy D, Perminova E. Clinical experience: ramucirumab with FOLFIRI/XELIRI as a second line for patients with metastatic gastric cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Reck M, Jotte R, Mok T, Lim DT, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas C, Barlesi F, Finley G, Nishio M, Lee A, Shankar G, Yu W, Socinski M. IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz063.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
12
|
Mok T, Socinski M, Reck M, Jotte R, Lim DT, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Siblot D, Thomas C, Barlesi F, Finley G, Lee A, Shankar G, Yu W, Kowanetz M, Lin W, Nishio M. IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy483.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
13
|
Van Cutsem E, Lesniewski-Kmak K, Saunders M, Wasan H, Argiles G, Borg C, Creemers GJ, Fedyanin M, Glynne-Jones R, Pfeiffer P, Punt C, Stroyakovskiy D, Ten Tije A, van de Wouw A, Cattan V, Desachy G, Amellal N, Moiseyenko V. Droplet digital PCR of circulating tumour DNA for the detection of RAS/BRAF mutation in metastatic colorectal cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.088] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Lesniewski-Kmak K, Moiseenko V, Saunders M, Wasan H, Argiles G, Borg C, Creemers G, Fedyanin M, Glynne-Jones R, Pfeiffer P, Punt C, Stroyakovskiy D, Ten Tije A, Van de Wouw A, Kanehisa A, Fougeray R, Busto NL, Amellal N, Van Cutsem E. Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy149.021] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
15
|
Jackisch C, Stroyakovskiy D, Pivot X, Ahn JS, Melichar B, Chen SC, Meyenberg C, Al-Sakaff N, Heinzmann D, Hegg R. Abstract PD3-11: Efficacy and safety of subcutaneous or intravenous trastuzumab in patients with HER2-positive early breast cancer after 5 years' treatment-free follow-up: Final analysis from the phase III, open-label, randomized HannaH study. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd3-11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background HannaH (NCT00950300) compared subcutaneous and intravenous trastuzumab (H SC and H IV) as neoadjuvant–adjuvant therapy for HER2-positive breast cancer. The co-primary endpoints of pathological complete response (pCR) and serum trough concentration at predose cycle 8 demonstrated noninferiority between H SC and H IV. Efficacy analyses of event-free survival (EFS) and overall survival (OS) at a median follow-up of 40 months supported this noninferiority. Safety analyses also confirmed the consistency of the safety profile across both arms. In this final follow-up analysis, we report the long-term efficacy and safety outcomes at 5 years of treatment-free follow-up (TFFU; 6 years in total). The correlation between total pCR (tpCR; absence of invasive neoplastic cells in ipsilateral nodes and the breast) and EFS was also explored.
Methods Enrolled patients (n=596; pts) were randomized to receive 4 cycles of docetaxel, then 4 cycles of 5-fluorouracil/epirubicin/cyclophosphamide concurrently with 3-weekly fixed-dose 600mg H SC or H IV (loading: 8mg/kg; maintenance: 6mg/kg) in the neoadjuvant setting. Post-surgery, pts received an additional 10 cycles of H SC or H IV in the adjuvant setting to complete 1 year of anti-HER2 therapy. EFS (time from randomization to local, regional, or distant recurrence, contralateral breast cancer, or death) and OS were calculated using the Kaplan-Meier method. Adverse events (AEs) and serious AEs were recorded and graded per standard criteria.
Results In total, 297 pts were randomized to the H SC arm and 299 to the H IV arm; 294 and 297 pts were included in the respective efficacy analysis populations. Median duration of follow-up (including TFFU) was 70.8 and 71.4 months in the H SC and H IV arms, respectively. EFS and OS were similar across both study arms (Table 1). Pts who achieved tpCR had longer EFS and OS vs. those who did not (Table 1).
Table 1 H SCH IVHazard Ratio (95% CI)6-year EFS, % (95% CI)n=294n=297 Overall65 (59;70)65 (60;71)0.98 (0.74;1.29)tpCR status*tpCRn=102n=90 80 (73;88)83 (75;91) no tpCRn=158n=173 57 (49;65)61 (54;69) 6-year OS, % (95% CI)n=294n=297 Overall84 (79;88)84 (79;88)0.94 (0.61;1.45)* Efficacy per protocol population
Cardiac AE incidence was low and consistent across study arms (Table 2).
Table 2Pts, n (%)H SC (n=297)H IV (n=298)Any AE290 (98)282 (95)≥ Grade 3 AE158 (53)160 (54)Serious AE65 (22)45 (15)Cardiac AE44 (15)42 (14)LVEF decline (≥10%-points from baseline to <50%)11 (3.8)12 (4.2)LVEF, left ventricular ejection fraction
Conclusion Long-term efficacy EFS and OS results confirmed the noninferiority of H SC compared with H IV, as demonstrated by pCR and pharmacokinetic endpoints. tpCR was associated with longer EFS and OS. The overall safety profile of H SC was consistent with that of H IV.
Citation Format: Jackisch C, Stroyakovskiy D, Pivot X, Ahn J-S, Melichar B, Chen S-C, Meyenberg C, Al-Sakaff N, Heinzmann D, Hegg R. Efficacy and safety of subcutaneous or intravenous trastuzumab in patients with HER2-positive early breast cancer after 5 years' treatment-free follow-up: Final analysis from the phase III, open-label, randomized HannaH study [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD3-11.
Collapse
Affiliation(s)
- C Jackisch
- Sana Klinikum Offenbach GmbH, Breast Cancer and Gynecology Cancer Center, Offenbach, Germany; City Clinical Oncology Hospital 62, Moscow, Russian Federation; CHU Jean Minjoz, Chemotherapy – Oncology, Besançon, France; Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul, Korea; Palacký University Medical School & Teaching Hospital, Olomouc, Czech Republic; Chang Gung Memorial Hospital, Taoyuan, Taiwan; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Product Development – Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Hospital Pérola Byington, São Paulo, Brazil
| | - D Stroyakovskiy
- Sana Klinikum Offenbach GmbH, Breast Cancer and Gynecology Cancer Center, Offenbach, Germany; City Clinical Oncology Hospital 62, Moscow, Russian Federation; CHU Jean Minjoz, Chemotherapy – Oncology, Besançon, France; Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul, Korea; Palacký University Medical School & Teaching Hospital, Olomouc, Czech Republic; Chang Gung Memorial Hospital, Taoyuan, Taiwan; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Product Development – Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Hospital Pérola Byington, São Paulo, Brazil
| | - X Pivot
- Sana Klinikum Offenbach GmbH, Breast Cancer and Gynecology Cancer Center, Offenbach, Germany; City Clinical Oncology Hospital 62, Moscow, Russian Federation; CHU Jean Minjoz, Chemotherapy – Oncology, Besançon, France; Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul, Korea; Palacký University Medical School & Teaching Hospital, Olomouc, Czech Republic; Chang Gung Memorial Hospital, Taoyuan, Taiwan; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Product Development – Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Hospital Pérola Byington, São Paulo, Brazil
| | - J-S Ahn
- Sana Klinikum Offenbach GmbH, Breast Cancer and Gynecology Cancer Center, Offenbach, Germany; City Clinical Oncology Hospital 62, Moscow, Russian Federation; CHU Jean Minjoz, Chemotherapy – Oncology, Besançon, France; Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul, Korea; Palacký University Medical School & Teaching Hospital, Olomouc, Czech Republic; Chang Gung Memorial Hospital, Taoyuan, Taiwan; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Product Development – Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Hospital Pérola Byington, São Paulo, Brazil
| | - B Melichar
- Sana Klinikum Offenbach GmbH, Breast Cancer and Gynecology Cancer Center, Offenbach, Germany; City Clinical Oncology Hospital 62, Moscow, Russian Federation; CHU Jean Minjoz, Chemotherapy – Oncology, Besançon, France; Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul, Korea; Palacký University Medical School & Teaching Hospital, Olomouc, Czech Republic; Chang Gung Memorial Hospital, Taoyuan, Taiwan; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Product Development – Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Hospital Pérola Byington, São Paulo, Brazil
| | - S-C Chen
- Sana Klinikum Offenbach GmbH, Breast Cancer and Gynecology Cancer Center, Offenbach, Germany; City Clinical Oncology Hospital 62, Moscow, Russian Federation; CHU Jean Minjoz, Chemotherapy – Oncology, Besançon, France; Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul, Korea; Palacký University Medical School & Teaching Hospital, Olomouc, Czech Republic; Chang Gung Memorial Hospital, Taoyuan, Taiwan; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Product Development – Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Hospital Pérola Byington, São Paulo, Brazil
| | - C Meyenberg
- Sana Klinikum Offenbach GmbH, Breast Cancer and Gynecology Cancer Center, Offenbach, Germany; City Clinical Oncology Hospital 62, Moscow, Russian Federation; CHU Jean Minjoz, Chemotherapy – Oncology, Besançon, France; Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul, Korea; Palacký University Medical School & Teaching Hospital, Olomouc, Czech Republic; Chang Gung Memorial Hospital, Taoyuan, Taiwan; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Product Development – Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Hospital Pérola Byington, São Paulo, Brazil
| | - N Al-Sakaff
- Sana Klinikum Offenbach GmbH, Breast Cancer and Gynecology Cancer Center, Offenbach, Germany; City Clinical Oncology Hospital 62, Moscow, Russian Federation; CHU Jean Minjoz, Chemotherapy – Oncology, Besançon, France; Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul, Korea; Palacký University Medical School & Teaching Hospital, Olomouc, Czech Republic; Chang Gung Memorial Hospital, Taoyuan, Taiwan; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Product Development – Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Hospital Pérola Byington, São Paulo, Brazil
| | - D Heinzmann
- Sana Klinikum Offenbach GmbH, Breast Cancer and Gynecology Cancer Center, Offenbach, Germany; City Clinical Oncology Hospital 62, Moscow, Russian Federation; CHU Jean Minjoz, Chemotherapy – Oncology, Besançon, France; Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul, Korea; Palacký University Medical School & Teaching Hospital, Olomouc, Czech Republic; Chang Gung Memorial Hospital, Taoyuan, Taiwan; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Product Development – Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Hospital Pérola Byington, São Paulo, Brazil
| | - R Hegg
- Sana Klinikum Offenbach GmbH, Breast Cancer and Gynecology Cancer Center, Offenbach, Germany; City Clinical Oncology Hospital 62, Moscow, Russian Federation; CHU Jean Minjoz, Chemotherapy – Oncology, Besançon, France; Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul, Korea; Palacký University Medical School & Teaching Hospital, Olomouc, Czech Republic; Chang Gung Memorial Hospital, Taoyuan, Taiwan; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Product Development – Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Hospital Pérola Byington, São Paulo, Brazil
| |
Collapse
|
16
|
Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 2018; 28:1631-1639. [PMID: 28475671 PMCID: PMC5834102 DOI: 10.1093/annonc/mdx176] [Citation(s) in RCA: 421] [Impact Index Per Article: 70.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2017] [Indexed: 02/07/2023] Open
Abstract
Background Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination dabrafenib and trametinib versus dabrafenib monotherapy in BRAF V600E/K-mutant metastatic melanoma. This study was continued to assess 3-year landmark efficacy and safety after ≥36-month follow-up for all living patients. Patients and methods This double-blind, phase 3 study enrolled previously untreated patients with BRAF V600E/K-mutant unresectable stage IIIC or stage IV melanoma. Patients were randomized to receive dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily) or dabrafenib plus placebo. The primary endpoint was PFS; secondary endpoints were OS, overall response, duration of response, safety, and pharmacokinetics. Results Between 4 May and 30 November 2012, a total of 423 of 947 screened patients were randomly assigned to receive dabrafenib plus trametinib (n = 211) or dabrafenib monotherapy (n = 212). At data cut-off (15 February 2016), outcomes remained superior with the combination: 3-year PFS was 22% with dabrafenib plus trametinib versus 12% with monotherapy, and 3-year OS was 44% versus 32%, respectively. Twenty-five patients receiving monotherapy crossed over to combination therapy, with continued follow-up under the monotherapy arm (per intent-to-treat principle). Of combination-arm patients alive at 3 years, 58% remained on dabrafenib plus trametinib. Three-year OS with the combination reached 62% in the most favourable subgroup (normal lactate dehydrogenase and <3 organ sites with metastasis) versus only 25% in the unfavourable subgroup (elevated lactate dehydrogenase). The dabrafenib plus trametinib safety profile was consistent with previous clinical trial observations, and no new safety signals were detected with long-term use. Conclusions These data demonstrate that durable (≥3 years) survival is achievable with dabrafenib plus trametinib in patients with BRAF V600-mutant metastatic melanoma and support long-term first-line use of the combination in this setting.
Collapse
Affiliation(s)
- G. V. Long
- Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, North Sydney, Australia
- Correspondence to: Prof. Georgina V. Long, Melanoma Institute Australia, The University of Sydney, 40 Rocklands Road, North Sydney 2060, NSW, Australia. Tel: +61-2-9911-7200; E-mail:
| | - K. T. Flaherty
- Developmental Therapeutics and Melanoma Programs, Massachusetts General Hospital Cancer Center, Boston, USA
| | | | - H. Gogas
- First Department of Medicine, “Laiko” General Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - E. Levchenko
- Petrov Research Institute of Oncology, Saint Petersburg, Russia
| | - F. de Braud
- Dipartimento di Medicina Oncologica, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - J. Larkin
- Royal Marsden NHS Foundation Trust, London, UK
| | - C. Garbe
- Department of Dermatology, University of Tübingen, Tübingen, Germany
| | - T. Jouary
- Service D'oncologie Médicale, Hopital Francois Mitterrand, Pau, France
| | - A. Hauschild
- Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany
| | - V. Chiarion-Sileni
- Melanoma and Oesophageal Oncology Unit, Veneto Oncology Institute–IRCCS, Padova, Italy
| | - C. Lebbe
- APHP Dermatology and CIC Departments, INSERM U976, University Paris Diderot, Paris, France
| | - M. Mandalà
- Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | - M. Millward
- Medical Oncology Department, Sir Charles Gairdner Hospital, Perth, Australia
| | - A. Arance
- Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - I. Bondarenko
- Dnipropetrovsk State Medical Academy, Clinical Hospital #4, Dnipropetrovsk, Ukraine
| | | | - J. Hansson
- Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - J. Utikal
- Skin Cancer Unit, German Cancer Research Center (DKFZ) and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim and Heidelberg, Germany
| | - V. Ferraresi
- Department of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy
| | - P. Mohr
- Dermatologisches Zentrum Buxtehude, Elbe Kliniken Buxtehude, Buxtehude, Germany
| | - V. Probachai
- Dnipropetrovsk Clinical Oncology Center of Dnipropetrovsk State Council, Dnipropetrovsk, Ukraine
| | - D. Schadendorf
- Department of Dermatology, University Hospital Essen, Essen, Germany
- German Cancer Consortium, Heidelberg, Germany
| | - P. Nathan
- Mount Vernon Cancer Centre, Northwood, UK
| | - C. Robert
- Gustave Roussy, Département de Médecine Oncologique, Service de Dermatologie et Université Paris-Sud, Faculté de Médecine, Villejuif, France
| | - A. Ribas
- Department of Medicine, Hematology/Oncology, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
| | - M. A. Davies
- Melanoma Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - S. R. Lane
- Novartis Pharmaceuticals Corporation, East Hanover, USA
| | - J. J. Legos
- Novartis Pharmaceuticals Corporation, East Hanover, USA
| | - B. Mookerjee
- Novartis Pharmaceuticals Corporation, East Hanover, USA
| | - J.-J. Grob
- Service de Dermatologie, Centre Hospitalo-Universitaire Timone, Aix-Marseille Université, Marseille, France
| |
Collapse
|
17
|
Esteva F, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskiy D, Pikiel J, Eniu A, Komov D, Zautashvili Z, Morar-Bolba G, Li R, Lifirenko I, Rusyn A, Lee S, Yu S, Stebbing J. Double-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx362.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Laktionov K, Arzumanyan A, Bolotina L, Breder V, Buevich N, Danilova A, Filippova E, Kornietskaya A, Kramchaninov M, Kushniruk E, Latipova D, Moiseenko F, Nikitina T, Orlov S, Orlova R, Protsenko S, Sarantseva K, Stroyakovskiy D, Ionova T. Multicenter observational study of the efficacy and safety of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
19
|
Forero A, Stroyakovskiy D, Cha E, Cruickshank S, Hasapidis J, Meyers ML, Slamon DJ. Abstract OT2-01-12: ENCORE 602: A randomized, placebo-controlled, double-blind, multicenter phase 2 study (with a phase 1b lead-in) of atezolizumab with or without entinostat in patients with advanced triple negative breast cancer (aTNBC). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot2-01-12] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Atezolizumab, a humanized anti-PDL1 antibody, has shown encouraging single agent activity in triple negative breast cancer. Entinostat is an oral, class I selective histone deacetylase (HDAC) inhibitor. In animal models, entinostat has been shown to selectively reduce immunosuppressive myeloid derived suppressor cells (MDSCs) and regulatory T cells (Tregs), enhancing response to immune checkpoint blockade. It is hypothesized that entinostat in combination with atezolizumab will show improved efficacy compared to atezolizumab alone.
Trial Design: ENCORE 602 is a Phase 1b/2 study evaluating the combination of entinostat plus atezolizumab in patients with aTNBC. The study has 2 phases: an open-label Dose Determination Phase (Phase 1b) followed by Phase 2. The objective of the Dose Determination Phase is to establish the recommended Phase 2 dose (RP2D) of weekly entinostat when given in combination with atezolizumab 1200 mg every 3 weeks. Phase 2 will evaluate the efficacy and safety of entinostat at the RP2D with atezolizumab in patients with aTNBC in a randomized (1:1), double-blind, placebo-controlled setting. The randomization will be stratified by geographic location (US vs ex-US).
Key Eligibility Criteria: Eligible patients will have 1) histologically- or cytologically-confirmed triple negative breast carcinoma that is either metastatic (stage IV of the TNM classification) or locally recurrent and not amenable to local curative treatment, 2) measurable disease based on imaging studies within 28 days before the first dose of study drug, and 3) received 1-2 prior lines of systemic therapy for locally recurrent and/or metastatic disease. Previous treatment with a PD-1/PD-L1-blocking antibody or a HDAC inhibitor is not permitted.
Specific Aims: In Phase 2, the primary endpoint is progression free survival (PFS), as assessed by the investigators using RECIST 1.1. Secondary endpoints include PFS by immune response RECIST (irRECIST), overall response rate, clinical benefit rate, overall survival, safety, and duration and time to response for those patients achieving a complete or partial response. Exploratory endpoints include PK, protein lysine acetylation, and immune correlates.
Statistical Methods: The primary analysis of PFS will be performed using a stratified log-rank test. Estimation of the hazard ratio for treatment effect will be determined using a stratified Cox proportional hazards model. 60 PFS events are estimated to provide 80% power to detect the targeted improvement in PFS with one-sided significance level of 0.1. An independent data safety monitoring board will meet at regular intervals to oversee trial conduct and patient safety.
Accrual: Up to 88 evaluable patients are anticipated if the study completes all phases of evaluation (6-18 patients in Phase 1b, 70 patients in Phase 2). The study was activated in May 2016 (NCT02708680).
Citation Format: Forero A, Stroyakovskiy D, Cha E, Cruickshank S, Hasapidis J, Meyers ML, Slamon DJ. ENCORE 602: A randomized, placebo-controlled, double-blind, multicenter phase 2 study (with a phase 1b lead-in) of atezolizumab with or without entinostat in patients with advanced triple negative breast cancer (aTNBC) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT2-01-12.
Collapse
Affiliation(s)
- A Forero
- University of Alabama at Birmingham, Birmingham, AL; Moscow City Oncology Hospital N62, Moscow, Russian Federation; Genentech, Inc., South San Francisco, CA; Syndax Pharmaceuticals, Inc., Waltham, MA; University of California Los Angeles, Los Angeles, CA
| | - D Stroyakovskiy
- University of Alabama at Birmingham, Birmingham, AL; Moscow City Oncology Hospital N62, Moscow, Russian Federation; Genentech, Inc., South San Francisco, CA; Syndax Pharmaceuticals, Inc., Waltham, MA; University of California Los Angeles, Los Angeles, CA
| | - E Cha
- University of Alabama at Birmingham, Birmingham, AL; Moscow City Oncology Hospital N62, Moscow, Russian Federation; Genentech, Inc., South San Francisco, CA; Syndax Pharmaceuticals, Inc., Waltham, MA; University of California Los Angeles, Los Angeles, CA
| | - S Cruickshank
- University of Alabama at Birmingham, Birmingham, AL; Moscow City Oncology Hospital N62, Moscow, Russian Federation; Genentech, Inc., South San Francisco, CA; Syndax Pharmaceuticals, Inc., Waltham, MA; University of California Los Angeles, Los Angeles, CA
| | - J Hasapidis
- University of Alabama at Birmingham, Birmingham, AL; Moscow City Oncology Hospital N62, Moscow, Russian Federation; Genentech, Inc., South San Francisco, CA; Syndax Pharmaceuticals, Inc., Waltham, MA; University of California Los Angeles, Los Angeles, CA
| | - ML Meyers
- University of Alabama at Birmingham, Birmingham, AL; Moscow City Oncology Hospital N62, Moscow, Russian Federation; Genentech, Inc., South San Francisco, CA; Syndax Pharmaceuticals, Inc., Waltham, MA; University of California Los Angeles, Los Angeles, CA
| | - DJ Slamon
- University of Alabama at Birmingham, Birmingham, AL; Moscow City Oncology Hospital N62, Moscow, Russian Federation; Genentech, Inc., South San Francisco, CA; Syndax Pharmaceuticals, Inc., Waltham, MA; University of California Los Angeles, Los Angeles, CA
| |
Collapse
|
20
|
Grob J, Robert C, Long G, Stroyakovskiy D, Levchenko E, Chiarion-Sileni V, Flaherty K, Nathan P, Ribas A, Davies M, Zhang J, Chen L, Mookerjee B, Redhu S, Schadendorf D. Health-related quality-of-life (HRQOL) impact of dabrafenib (D) and trametinib (T) vs BRAF inhibitor (BRAFi) monotherapy by lactate dehydrogenase (LDH) in patients (pts) with BRAF V600–mutant melanoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw379.32] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Robert C, Schadendorf D, Long G, Stroyakovskiy D, Levchenko E, Chiarion-Sileni V, Flaherty K, Nathan P, Ribas A, Davies M, Zhang J, Chen L, Mookerjee B, Redhu S, Grob J. Analysis of patient-reported outcomes by disease progression status in patients (pts) with BRAF V600–mutant metastatic melanoma in the COMBI-d and COMBI-v trials. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw379.35] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroyakovskiy D, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsová I, Hauschild A, Mookerjee B, Legos J, Zhang Y, Lane S, Schadendorf D. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw435.37] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Dréno B, Bartley K, Ascierto P, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Chang I, Hack S, Larkin J, McArthur G, Ribas A. Évaluation de la qualité de vie (QdV) chez des patients atteints d’un mélanome métastatique traités par vemurafenib (V) et cobimetinib (C). Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
24
|
Ahn JS, Jackisch C, Hegg R, Stroyakovskiy D, Melichar B, Chen SC, Crepelle-Flechais A, Lauer S, Shing M, Pivot X. 55O_PR Phase III HannaH study of subcutaneous or intravenous trastuzumab for HER2-positive early breast cancer: Exploratory subgroup analyses of pathological complete response and 3-year event-free survival by body weight and anti-drug antibody status. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv519.04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
25
|
Jackisch C, Hegg R, Stroyakovskiy D, Ahn J, Melichar B, Chen S, Crepelle-Fléchais A, Lauer S, Shing M, Pivot X. 1945 Phase III HannaH study of subcutaneous or intravenous trastuzumab for HER2-positive early breast cancer: Exploratory subgroup analyses of pathological complete response and 3-year event-free survival according to body weight and anti-drug antibody status. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30893-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
26
|
Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroyakovskiy D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Mookerjee B, Legos J, Schadendorf D. 3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31820-2] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
27
|
Jackisch C, Hegg R, Stroyakovskiy D, Ahn J, Melichar B, Chen S, Crepelle-Flechais A, Heinzmann D, Shing M, Pivot X. P201 Subcutaneous versus intravenous trastuzumab in early breast cancer: 2-year follow-up of HannaH. Breast 2015. [DOI: 10.1016/s0960-9776(15)70235-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
28
|
Jackisch C, Kim SB, Semiglazov V, Melichar B, Pivot X, Hillenbach C, Stroyakovskiy D, Lum BL, Elliott R, Weber HA, Ismael G. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Ann Oncol 2014; 26:320-5. [PMID: 25403587 DOI: 10.1093/annonc/mdu524] [Citation(s) in RCA: 77] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND HannaH (NCT00950300) was a phase III, randomized, international, open-label study that compared pharmacokinetics (PK), efficacy, and safety of two different trastuzumab formulations [subcutaneous (s.c.) and intravenous (i.v.)] in HER2-positive, operable, locally advanced, or inflammatory breast cancer in the neoadjuvant/adjuvant setting. The co-primary end points, to show noninferiority of s.c. versus i.v. trastuzumab in terms of serum concentration (Ctrough) and pathologic complete response (pCR) were met; safety profiles were comparable at 12 months' median follow-up. Secondary end points included safety and tolerability, PK profile, immunogenicity, and event-free survival (EFS). We now report updated safety and efficacy data after a median follow-up of 20 months. PATIENTS AND METHODS Patients (N = 596) were treated with eight cycles of neoadjuvant chemotherapy, administered concurrently with 3-weekly s.c. trastuzumab (fixed dose of 600 mg) or the standard weight-based i.v. method. Following surgery, patients continued trastuzumab treatment to complete 1 year of therapy. Updated analyses of PK, efficacy, safety, and immunogenicity data were carried out. RESULTS s.c. trastuzumab was generally well tolerated and the incidence of adverse events (AEs), including grade 3 or 4 AEs, between treatment groups was comparable. A slightly higher incidence of serious AEs (SAEs), mainly due to infections, was reported with s.c. treatment {64 [21.5%; 95% confidence interval (CI) 17.0%-26.7%] versus 42 (14.1%; 95% CI 10.4%-18.6%) in the i.v. group}; however, the differences were small and often based on rare events, with no observable pattern across reported events. An early analysis of EFS showed rates of 95% in both groups 1 year postrandomization. Exploratory analyses did not reveal an association between toxicity and body weight or exposure. CONCLUSIONS Overall, the safety profile of s.c. trastuzumab was consistent with the previously published data from HannaH and the known safety profile of i.v. trastuzumab. EFS rates were comparable between the i.v. and s.c. groups. CLINICAL TRIAL NUMBER NCT00950300.
Collapse
Affiliation(s)
- C Jackisch
- Department of Obstetrics and Gynecology and Breast Cancer and Gynecology Cancer Center, Sana Klinikum Offenbach GmbH, Offenbach, Germany
| | - S-B Kim
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - V Semiglazov
- Department of Surgery, NN Petrov Research Institute of Oncology, St Petersburg, Russia
| | - B Melichar
- Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic
| | - X Pivot
- Chemotherapy-Oncology, CHU Jean Minjoz, Besançon, France
| | - C Hillenbach
- Department of Biopharmaceuticals, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - D Stroyakovskiy
- Chemotherapeutic Department, City Clinical Oncology Hospital 62, Moscow, Russia
| | | | - R Elliott
- BioAnalytical Sciences, Genentech, South San Francisco, USA
| | - H A Weber
- Department of Biopharmaceuticals, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - G Ismael
- Hospital Amaral Carvalho, Jaú, Brazil
| |
Collapse
|
29
|
Schadendorf D, Amonkar M, Stroyakovskiy D, Levchenko E, Gogas H, De Braud F, Grob J., Bondarenko I, Garbe C, Lebbe C, Larkin J, Chiarion-Sileni V, Millward M, Arance A, Mandalà M, Casey M, Demarini D, Irani J, Aktan G, Long G. Combi-D: Quality of Life (Qol) Impact of the Combination of Dabrafenib and Trametinib (D + T) Versus Dabrafenib Monotherapy (D) in Patients with Braf V600E/K Unresectable or Metastatic Melanoma in a Phase III Trial. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu344.7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Melichar B, Stroyakovskiy D, Ahn J, Kopp M, Srimuninnimit V, Kunz G, Li J, van der Horst T, Muehlbauer S, Jackisch C. Pathological Complete Response to Trastuzumab Subcutaneous Fixed-Dose Formulation in the Hannah Study: Subgroup Analysis of Patient Demographics and Tumor Characteristics and Influence of Body Weight (BW) and Serum Trough Concentration (Ctrough) of Trastuzumab. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32884-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
31
|
Jackisch C, Stroyakovskiy D, Muehlbauer S, Heinzmann D, Kopp M, Ahn J, Staroslawska E, Falcon S, Pivot X, Ismael G. 1BA Subcutaneous Administration of Trastuzumab in Patients with HER2-positive Early Breast Cancer: Results From the Phase III Randomised, Open-label, Multi-centre Neoadjuvant-adjuvant HannaH Study. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70068-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
32
|
Gonzalez-Martin A, Gladieff L, Stroyakovskiy D, Tholander B, Gore M, Scambia G, Kristensen G, Diz M, Bollag D, Pignata S. 8002 ORAL Front-line Bevacizumab (BEV) Combined With Weekly Paclitaxel (wPAC) and Carboplatin (C) for Ovarian Cancer (OC): Safety Results From the Concurrent Chemotherapy (CT) Phase of the OCTAVIa Study. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72090-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
33
|
Smith I, Pierga JY, Biganzoli L, Cortés-Funes H, Thomssen C, Pivot X, Fabi A, Xu B, Stroyakovskiy D, Franke F, Kaufman B, Mainwaring P, Pienkowski T, De Valk B, Kwong A, González-Trujillo J, Koza I, Petrakova K, Pereira D, Pritchard K. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Ann Oncol 2011; 22:595-602. [DOI: 10.1093/annonc/mdq430] [Citation(s) in RCA: 85] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
|
34
|
Thatcher N, Stroyakovskiy D, Zhou C, Bearz A, Isla D, Griesinger F, Pavlakis N. MO19390 (SAiL): Incidence of hemorrhage with first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19000] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19000 Background: MO19390 (SAiL) is an international, multicenter, open-label study evaluating the safety of first-line Bv in combination with a range of chemotherapy regimens in over 2,000 patients (pts). We report interim safety data with a focus on the incidence of serious bleeding events, including pulmonary hemorrhage. Methods: Primary endpoint was safety; secondary endpoints included time to disease progression and overall survival. Eligibility criteria included: non-squamous NSCLC with no prior chemotherapy, no uncontrolled hypertension (systolic >150 mmHg and/or diastolic >100 mmHg) or active cardiovascular disease at baseline, ECOG PS 0–2, no history of grade [g])>2 hemoptysis, and no evidence of tumor abutting or invading major blood vessels. Pts received Bv (7.5 or 15mg/kg) with chemotherapy for up to six cycles, then non-progressors proceeded to receive Bv until disease progression. Results: Interim analyses were available for a safety population of 2,008 pts (data cut-off July 2008). Baseline characteristics for pts were (%): male 60.1; Caucasian/Asian/other 80.1/15.6/4.3; stage IIIB/IV 19.5/80.5 (no data for 3 pts); adenocarcinoma/large cell/other 85.8/7.1/7.1; central tumor location yes/no (Y/N) 27.3/72.7; cavitated tumor Y/N 2.6/97.4; smoking history Y/N 70/30; ECOG PS 0/1/2 38.1/56.1/5.8. The median age was 59 years. Serious bleeding events (g≥3) of any cause were reported in 43 pts (2.1%). Bv-related bleeding events (g≥3) were reported in 16 pts (0.8%), including hemoptysis in 5 pts (0.2%) and gastrointestinal hemorrhage in 3 pts (0.1%). Conclusions: In Bv-treated pts, significant bleeding and hemoptysis are rare events. Our results confirm the well established and manageable safety profile of Bv-based therapy in eligible non-squamous NSCLC pts. Updated results will be presented. [Table: see text]
Collapse
Affiliation(s)
- N. Thatcher
- The Christie Hospital, Manchester, United Kingdom; Moscow City Oncology Hospital, Moscow, Russian Federation; Shanghai Pulmonary Hospital, Shanghai, China; Centro di Riferimento Oncologico, Aviano, Italy; Hospital Clínico Lozano Blesa, Zaragoza, Spain; Pius-Hospital Oldenburg, Oldenburg, Germany; Royal North Shore Hospital, Sydney, Australia
| | - D. Stroyakovskiy
- The Christie Hospital, Manchester, United Kingdom; Moscow City Oncology Hospital, Moscow, Russian Federation; Shanghai Pulmonary Hospital, Shanghai, China; Centro di Riferimento Oncologico, Aviano, Italy; Hospital Clínico Lozano Blesa, Zaragoza, Spain; Pius-Hospital Oldenburg, Oldenburg, Germany; Royal North Shore Hospital, Sydney, Australia
| | - C. Zhou
- The Christie Hospital, Manchester, United Kingdom; Moscow City Oncology Hospital, Moscow, Russian Federation; Shanghai Pulmonary Hospital, Shanghai, China; Centro di Riferimento Oncologico, Aviano, Italy; Hospital Clínico Lozano Blesa, Zaragoza, Spain; Pius-Hospital Oldenburg, Oldenburg, Germany; Royal North Shore Hospital, Sydney, Australia
| | - A. Bearz
- The Christie Hospital, Manchester, United Kingdom; Moscow City Oncology Hospital, Moscow, Russian Federation; Shanghai Pulmonary Hospital, Shanghai, China; Centro di Riferimento Oncologico, Aviano, Italy; Hospital Clínico Lozano Blesa, Zaragoza, Spain; Pius-Hospital Oldenburg, Oldenburg, Germany; Royal North Shore Hospital, Sydney, Australia
| | - D. Isla
- The Christie Hospital, Manchester, United Kingdom; Moscow City Oncology Hospital, Moscow, Russian Federation; Shanghai Pulmonary Hospital, Shanghai, China; Centro di Riferimento Oncologico, Aviano, Italy; Hospital Clínico Lozano Blesa, Zaragoza, Spain; Pius-Hospital Oldenburg, Oldenburg, Germany; Royal North Shore Hospital, Sydney, Australia
| | - F. Griesinger
- The Christie Hospital, Manchester, United Kingdom; Moscow City Oncology Hospital, Moscow, Russian Federation; Shanghai Pulmonary Hospital, Shanghai, China; Centro di Riferimento Oncologico, Aviano, Italy; Hospital Clínico Lozano Blesa, Zaragoza, Spain; Pius-Hospital Oldenburg, Oldenburg, Germany; Royal North Shore Hospital, Sydney, Australia
| | - N. Pavlakis
- The Christie Hospital, Manchester, United Kingdom; Moscow City Oncology Hospital, Moscow, Russian Federation; Shanghai Pulmonary Hospital, Shanghai, China; Centro di Riferimento Oncologico, Aviano, Italy; Hospital Clínico Lozano Blesa, Zaragoza, Spain; Pius-Hospital Oldenburg, Oldenburg, Germany; Royal North Shore Hospital, Sydney, Australia
| |
Collapse
|
35
|
Pierga J, Pritchard KI, Cortes-Funes H, Biganzoli L, Thomssen C, Franke FA, Smith IE, Bogdanova N, Stroyakovskiy D. MO19391: An open-label safety study of bevacizumab plus taxane-based therapy as first-line treatment of patients with locally recurrent (LR) or metastatic breast cancer (MBC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.1140] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|